These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25295716)

  • 1. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
    Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
    Höchel J; Schuett B; Ludwig M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):856-66. PubMed ID: 25138681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.
    Winkler J; Goldammer M; Ludwig M; Rohde B; Zurth C
    Eur J Drug Metab Pharmacokinet; 2015 Dec; 40(4):389-99. PubMed ID: 24997757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
    Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.
    Junge W; Heger-Mahn D; Trummer D; Merz M
    Drugs R D; 2013 Sep; 13(3):223-33. PubMed ID: 24043457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Anderson GD
    Br J Clin Pharmacol; 2002 Feb; 53(2):141-6. PubMed ID: 11851637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.
    Zhang C; Li H; Xiong X; Zhai S; Wei Y; Zhang S; Zhang Y; Xu L; Liu L
    Drug Des Devel Ther; 2017; 11():725-731. PubMed ID: 28331292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
    Zurth C; Schuett B; Casjens M; Ludwig M; Waellnitz K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):245-55. PubMed ID: 27136904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
    Bhardwaj R; Stringfellow JC; Morris B; Croop RS; Bertz RJ
    Headache; 2023 May; 63(5):652-662. PubMed ID: 37140071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL; Reinecke I; Bangerter K; Merz M
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.
    Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
    Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women.
    Waellnitz K; Duijkers I; Klipping C; Rautenberg T; Rohde B; Zurth C
    J Obstet Gynaecol; 2016; 36(1):106-13. PubMed ID: 26421957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.